ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX)
CUSIP: 45256X103
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 1,124,549,707
- Total 13F shares
- 93,497,152
- Share change
- -1,924,815
- Total reported value
- $714,518,178
- Put/Call ratio
- 136%
- Price per share
- $7.67
- Number of holders
- 262
- Value change
- -$9,461,664
- Number of buys
- 184
- Number of sells
- 46
Quarterly Holders Quick Answers
What is CUSIP 45256X103?
CUSIP 45256X103 identifies IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 45256X103:
Top shareholders of IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Cambridge Equities, LP |
13D/G
3/4/5
|
Patrick Soon-Shiong · 10%+ Owner |
66%
|
745,576,456
|
$4,406,356,855 | +$9,487,063 | 23 Feb 2026 | |
| Patrick Soon-Shiong |
3/4/5
|
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner |
—
mixed-class rows
|
288,867,272
mixed-class rows
|
$572,512,835 | — | 31 Mar 2026 | |
| CALIFORNIA CAPITAL EQUITY, LLC |
3/4/5
|
10%+ Owner |
26%
|
288,752,943
|
$571,730,825 | — | 31 Mar 2026 | |
| MP 13 Ventures, LLC |
3/4/5
|
10%+ Owner |
26%
|
288,752,943
|
$571,730,825 | — | 31 Mar 2026 | |
| Nant Capital, LLC |
3/4/5
|
10%+ Owner |
26%
|
288,752,943
|
$571,730,825 | — | 31 Mar 2026 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.9%
|
32,777,257
|
$64,898,969 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
2.3%
|
25,601,219
|
$50,690,414 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.5%
|
16,455,703
|
$32,582,292 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
1.3%
|
14,224,224
|
$28,163,963 | — | 31 Dec 2025 | |
| Barry J. Simon |
3/4/5
|
Director |
—
mixed-class rows
|
2,866,066
mixed-class rows
|
$16,909,279 | -$1,783,602 | 24 Feb 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.7%
|
7,920,178
|
$15,684,103 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.55%
|
6,152,684
|
$12,182,314 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.45%
|
5,106,214
|
$10,110,303 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.42%
|
4,717,843
|
$9,341,329 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.32%
|
3,654,499
|
$7,235,908 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.31%
|
3,446,540
|
$6,824,149 | — | 31 Dec 2025 | |
| AlphaCore Capital LLC |
13F
|
Company |
0.27%
|
3,000,544
|
$5,941,077 | — | 31 Dec 2025 | |
| Richard Adcock |
3/4/5
|
CEO & President, Director |
—
mixed-class rows
|
712,783
mixed-class rows
|
$5,917,675 | — | 22 Feb 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.22%
|
2,501,666
|
$4,953,299 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.22%
|
2,444,163
|
$4,839,444 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.21%
|
2,382,503
|
$4,717,356 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.21%
|
2,333,333
|
$4,619,999 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.2%
|
2,230,112
|
$4,415,622 | — | 31 Dec 2025 | |
| Kercheville Advisors, LLC |
13F
|
Company |
0.05%
|
584,174
|
$4,287,837 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.18%
|
1,995,607
|
$3,951,301 | — | 31 Dec 2025 | |
| Voleon Capital Management LP |
13F
|
Company |
0.13%
|
1,514,586
|
$2,998,880 | — | 31 Dec 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.13%
|
1,494,713
|
$2,959,532 | — | 31 Dec 2025 | |
| David C. Sachs |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
340,794
mixed-class rows
|
$2,889,293 | — | 22 Feb 2026 | |
| Skandinaviska Enskilda Banken AB (publ) |
13F
|
Company |
0.12%
|
1,324,871
|
$2,616,620 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.11%
|
1,231,770
|
$2,438,905 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.11%
|
1,219,879
|
$2,415,361 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.1%
|
1,142,256
|
$2,261,667 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.08%
|
882,327
|
$1,747,007 | — | 31 Dec 2025 | |
| Clearwater Capital Advisors, LLC |
13F
|
Company |
0.08%
|
845,084
|
$1,673,267 | — | 31 Dec 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.07%
|
766,908
|
$1,518,478 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.06%
|
704,574
|
$1,395,057 | — | 31 Dec 2025 | |
| ALLEN HOLDING INC /NY |
13F
|
Company |
0.06%
|
687,571
|
$1,361,391 | — | 31 Dec 2025 | |
| Accurate Wealth Management, LLC |
13F
|
Company |
0.05%
|
560,000
|
$1,304,800 | — | 31 Dec 2025 | |
| Swiss National Bank |
13F
|
Company |
0.06%
|
652,400
|
$1,291,752 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.06%
|
633,094
|
$1,253,526 | — | 31 Dec 2025 | |
| SHEETS SMITH WEALTH MANAGEMENT |
13F
|
Company |
0.06%
|
631,975
|
$1,251,311 | — | 31 Dec 2025 | |
| Sculptor Capital LP |
13F
|
Company |
0.06%
|
619,000
|
$1,225,620 | — | 31 Dec 2025 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.05%
|
607,330
|
$1,202,513 | — | 31 Dec 2025 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.02%
|
196,200
|
$1,165,000 | — | 31 Dec 2025 | |
| John C. Thomas |
3/4/5
|
Former Director |
—
class O/S missing
|
216,363
|
$1,086,143 | — | 31 Dec 2021 | |
| Regan J. Lauer |
3/4/5
|
Chief Accounting Officer |
—
mixed-class rows
|
119,940
mixed-class rows
|
$1,035,917 | — | 22 Feb 2026 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.05%
|
515,920
|
$1,021,521 | — | 31 Dec 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.04%
|
493,445
|
$977,021 | — | 31 Dec 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.04%
|
461,176
|
$913,128 | — | 31 Dec 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.04%
|
458,059
|
$906,957 | — | 31 Dec 2025 |
Institutional Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q1 2026
As of 31 Mar 2026,
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) was held by
262 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
93,497,152 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD PORTFOLIO MANAGEMENT LLC, VANGUARD CAPITAL MANAGEMENT LLC, UBS Group AG, SEB Asset Management AB, VANGUARD FIDUCIARY TRUST CO, Private Advisor Group, LLC, JPMORGAN CHASE & CO, FEDERATED HERMES, INC., and Cetera Investment Advisers.
This page lists
262
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
264
Q1 2026 holders
262
Holder diff
-2
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.